Investor Presentaiton

BND-22: Summary (OPTIONAL) Using In-house research capabilities BND-22 was developed from scientific concept to clinical trials First-in-human, phase 1 study, Initiated in Q1 2021 (single agent and combination with approved therapeutics) A humanized IgG4 antibody that enhances the anti- tumor activity of immune cells by blocking ILT2 from binding to HLA-G and MHC-I BND-22 was licensed to Sanofi with upfront payment of $125M, over $1B in milestones and royalty payments BIOND BIOLOGICS Biond Biologics Corporate Presentation | May 2021 | Non-confidential 14

View entire presentation